Analyst Reco. Adagene Inc.

Equities

ADAG

US0053291078

Delayed Nasdaq Other stock markets 14:29:52 2024-05-08 EDT			5-day change	1st Jan Change
2.184 ^USD	-2.75%		-6.28%	+13.06%

03-29	Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-29	Adagene Inc. Announces Board Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Adagene to $5 From $7, Maintains Overweight Rating	23-01-24	MT
HC Wainwright Starts Adagene at Buy With $5 Price Target	22-12-07	MT
Morgan Stanley Cuts Price Target on Adagene to $7 From $15, Maintains Overweight Rating	22-09-09	MT
Berenberg Emerging Biotech Conference	22-05-18	FA
Morgan Stanley Adjusts Adagene's Price Target to $15 From $27, Reiterates Overweight Rating	22-02-01	MT
Morgan Stanley Adjusts Adagene's Price Target to $27 from $33, Keeps Overweight Rating	22-01-06	MT
ADAGENE : Morgan Stanley Adjusts Price Target on Adagene to $33 From $34, Maintains Overweight Rating	21-07-16	MT
ADAGENE : China Renaissance Starts Adagene at Buy With $40.57 Price Target	21-06-25	MT
ADAGENE : Morgan Stanley Starts Adagene at Overweight With $34 Price Target	21-03-08	MT
ADAGENE : Jefferies & Co Initiates Coverage on Adagene With Buy Rating, $33 Price Target	21-03-08	MT
ADAGENE : Goldman Sachs Initiates Coverage on Adagene With Buy Rating, $29 Price Target	21-03-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW